Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 558 common stock shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On April 17, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction involving the company's common stock.
- The transaction involved the disposal of 558 shares to satisfy tax withholding requirements upon the vesting of restricted stock units.
- The shares were disposed of at a price of $10.34 per share.
- Following the transaction, Miller directly owns 39,893 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a standard Form 4 filing, which is a routine disclosure of stock transactions by company insiders. It's a common practice for executives to sell shares to cover tax obligations when restricted stock units vest.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/17/2024 | Date of stock transaction (disposal of shares). |
| 04/19/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.